HBV-positive cirrhotic
Conditions
Interventions
Cholestyramine Group:Cholestyramine
Control Group:Entecavir dispersible tablet
Sponsors
Department of Gastroenterology, Clinical medical college and the first affiliated hospital of Chengdu medical college
Eligibility
Sex/Gender
All
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: 1. Aged between 18 and 75 years; 2. HBsAg positive for 6 months; 3.HBV-DNA >2, 000IU/ml 4. Bile acid > 10umol/L; 5. Liver cirrhosis was confirmed by ultrasound, CT or MRI scanning or pathological biopsy.
Exclusion criteria
Exclusion criteria: 1. Unable to comply with or refused to sign the informed consent form; 2. Allergy history to colecenide; 3. Gastroscopy showed severe esophageal and gastric varices, or positive red sign (RC); 4. Have a history of bleeding from esophageal and gastric varices or hepatic encephalopathy; 5. Child Pugh score = 10; 6. Platelets 210 g/w, female alcohol intake > 140 g/w; 8. Other causes of liver disease, including autoimmunity, drug-induced liver injury, alcohol or genetic metabolic liver disease, or liver cancer; 9. Other systems such as circulatory, respiratory, urinary and other serious diseases or cancers; 10. Have a history of intestinal resection, splenectomy or embolization; 11. HIV infection or other organ dysfunction such as diabetes, renal insufficiency, autoimmune disease, thyroid disease; 12. Hepatitis A, C, D or E virus infection; 13. Pregnant or lactating women; 14. Use history of metformin; 15. Antibiotics were used within 7 days before enrollment; 16. Use immunomodulator within 30 days before enrollment; 17. Take probiotics; 18. Take antiviral drugs other than entecavir; 19. Participate in another clinical trial. 20. The researcher determined other conditions that are not suitable for this study; 21. Subjects can withdraw from the test at any time in the following circumstances: the patient has serious adverse events, the investigator thinks it is necessary to interrupt the test, and the patient needs to end the study period.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Serum endotoxin; | — |
Secondary
| Measure | Time frame |
|---|---|
| HBV assessment;Blood test for liver function;Liver fibrosis and cirrhosis assessment;Incidence of adverse events; | — |
Countries
China
Contacts
Public ContactXiangsheng Fu
Department of Gastroenterology, Clinical medical college and the first affiliated hospital of Chengdu medical college
Outcome results
None listed